301 related articles for article (PubMed ID: 38474014)
21. Viral DNA replication-dependent DNA damage response activation during BK polyomavirus infection.
Verhalen B; Justice JL; Imperiale MJ; Jiang M
J Virol; 2015 May; 89(9):5032-9. PubMed ID: 25694603
[TBL] [Abstract][Full Text] [Related]
22. Adefovir dipivoxil induces DNA replication stress and augments ATR inhibitor-related cytotoxicity.
Patel A; Seraia E; Ebner D; Ryan AJ
Int J Cancer; 2020 Sep; 147(5):1474-1484. PubMed ID: 32159854
[TBL] [Abstract][Full Text] [Related]
23. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
Gulliver C; Hoffmann R; Baillie GS
Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
[TBL] [Abstract][Full Text] [Related]
24. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ
Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113
[TBL] [Abstract][Full Text] [Related]
25. Expression variations of DNA damage response genes ATM and ATR in blood cancer patients.
Parvez A; Mahjabeen I; Mehmood A; Khan AU; Nisar A; Kayani MA
Mol Genet Genomics; 2023 Sep; 298(5):1173-1183. PubMed ID: 37338595
[TBL] [Abstract][Full Text] [Related]
26. Investigation of switch from ATM to ATR signaling at the sites of DNA damage induced by low and high LET radiation.
Saha J; Wang M; Cucinotta FA
DNA Repair (Amst); 2013 Dec; 12(12):1143-51. PubMed ID: 24238855
[TBL] [Abstract][Full Text] [Related]
27. ATM and ATR as therapeutic targets in cancer.
Weber AM; Ryan AJ
Pharmacol Ther; 2015 May; 149():124-38. PubMed ID: 25512053
[TBL] [Abstract][Full Text] [Related]
28. A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade.
Ngoi NYL; Peng G; Yap TA
Annu Rev Med; 2022 Jan; 73():231-250. PubMed ID: 34644155
[TBL] [Abstract][Full Text] [Related]
29. The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
Wengner AM; Siemeister G; Lücking U; Lefranc J; Wortmann L; Lienau P; Bader B; Bömer U; Moosmayer D; Eberspächer U; Golfier S; Schatz CA; Baumgart SJ; Haendler B; Lejeune P; Schlicker A; von Nussbaum F; Brands M; Ziegelbauer K; Mumberg D
Mol Cancer Ther; 2020 Jan; 19(1):26-38. PubMed ID: 31582533
[TBL] [Abstract][Full Text] [Related]
30. DNA damage sensing by the ATM and ATR kinases.
Maréchal A; Zou L
Cold Spring Harb Perspect Biol; 2013 Sep; 5(9):. PubMed ID: 24003211
[TBL] [Abstract][Full Text] [Related]
31. ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress.
Myers K; Gagou ME; Zuazua-Villar P; Rodriguez R; Meuth M
PLoS Genet; 2009 Jan; 5(1):e1000324. PubMed ID: 19119425
[TBL] [Abstract][Full Text] [Related]
32. Marek's Disease Virus Disables the ATR-Chk1 Pathway by Activating STAT3.
Lian X; Bao C; Li X; Zhang X; Chen H; Jung YS; Qian Y
J Virol; 2019 May; 93(9):. PubMed ID: 30787154
[TBL] [Abstract][Full Text] [Related]
33. Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.
Sanjiv K; Hagenkort A; Calderón-Montaño JM; Koolmeister T; Reaper PM; Mortusewicz O; Jacques SA; Kuiper RV; Schultz N; Scobie M; Charlton PA; Pollard JR; Berglund UW; Altun M; Helleday T
Cell Rep; 2016 Jan; 14(2):298-309. PubMed ID: 26748709
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
35. ATR phosphorylates SMARCAL1 to prevent replication fork collapse.
Couch FB; Bansbach CE; Driscoll R; Luzwick JW; Glick GG; Bétous R; Carroll CM; Jung SY; Qin J; Cimprich KA; Cortez D
Genes Dev; 2013 Jul; 27(14):1610-23. PubMed ID: 23873943
[TBL] [Abstract][Full Text] [Related]
36. Versatility of the Mec1
Corcoles-Saez I; Dong K; Cha RS
Curr Genet; 2019 Jun; 65(3):657-661. PubMed ID: 30610294
[TBL] [Abstract][Full Text] [Related]
37. S-phase-dependent p50/NF-кB1 phosphorylation in response to ATR and replication stress acts to maintain genomic stability.
Crawley CD; Kang S; Bernal GM; Wahlstrom JS; Voce DJ; Cahill KE; Garofalo A; Raleigh DR; Weichselbaum RR; Yamini B
Cell Cycle; 2015; 14(4):566-76. PubMed ID: 25590437
[TBL] [Abstract][Full Text] [Related]
38. Targeting ATR in cancer medicine.
Sundar R; Brown J; Ingles Russo A; Yap TA
Curr Probl Cancer; 2017; 41(4):302-315. PubMed ID: 28662958
[TBL] [Abstract][Full Text] [Related]
39. Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation.
Lopez-Pelaez M; Young L; Vazquez-Chantada M; Nelson N; Durant S; Wilkinson RW; Poon E; Gaspar M; Valge-Archer V; Smith P; Dovedi SJ
Oncoimmunology; 2022; 11(1):2117321. PubMed ID: 36117525
[TBL] [Abstract][Full Text] [Related]
40. Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress.
Yan S; Sorrell M; Berman Z
Cell Mol Life Sci; 2014 Oct; 71(20):3951-67. PubMed ID: 24947324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
